Display options
Share it on

J Alzheimers Dis. 2021 Oct 19; doi: 10.3233/JAD-210546. Epub 2021 Oct 19.

The Diagnostic Value of a Short Memory Test: The TNI-93.

Journal of Alzheimer's disease : JAD

Cendrine Foucard, Juliette Palisson, Catherine Belin, Chloé Bereaux, Julien Dumurgier, Claire Paquet, Bertrand Degos, Elodie Bouaziz-Amar, Didier Maillet, Marion Houot, Béatrice Garcin

Affiliations

  1. Neurology Department, Avicenne hospital, APHP, Bobigny, Sorbonne Paris Nord, France.
  2. Neurology Department, Saint-Louis hospital, APHP, Paris, France.
  3. Université de Paris, Cognitive Neurology Center, Lariboisiere - Fernand Widal Hospital, AP-HP, Paris, France.
  4. Dynamics and Pathophysiology of Neuronal Networks Team, Center for Interdisciplinary Research in Biology, Collège de France, CNRS UMR7241/INSERM U1150, Université PSL, Paris, France.
  5. Department of Biochemistry and Molecular Biology - GHU AP-HP.Nord - University of Paris, Lariboisière Hospital; INSERM U1144, University of Paris, Paris, France.
  6. Centre of Excellence of Neurodegenerative Disease (CoEN), Salpêtrière Hospital, Boulevard de l'hôpital, Paris, France.
  7. Institute of Memory and Alzheimer's Disease (IM2A), Department of Neurology, Salpêtrière Hospital, AP-HP, Paris, France.
  8. Clinical Investigation Centre, Institut du Cerveau et de la Moelle épinière (ICM), Salpêtrière Hospital, Paris, France.
  9. Institut du Cerveau et de la Moelle épinière - ICM, Inserm U1127, CNRS UMR 7225, Sorbonne Université, Paris, France.

PMID: 34690140 DOI: 10.3233/JAD-210546

Abstract

BACKGROUND: The TNI-93 is a quick memory test designed for all patients regardless of their education level. A significant proportion of patients with Alzheimer's disease (AD) are illiterate or poorly educated, and only a few memory tests are adapted for these patients.

OBJECTIVE: In this study we aimed at assessing the diagnostic value of the TNI-93 for diagnosis of patients with biologically confirmed amyloid status.

METHODS: We included all patients who had an analysis of AD cerebrospinal fluid biomarkers, a neuropsychological assessment including a TNI-93 and an anatomical brain imaging at Avicenne Hospital between January 2009 and November 2019. We compared the TNI-93 scores in patients with amyloid abnormalities (A+) and patients without amyloid abnormalities (A-) according to the AT(N) diagnostic criteria.

RESULTS: 108 patients were included (mean age: 66.9±8.5 years old, mean education level: 8.9±5.2 years). Patients from the A + group (N= 80) were significantly more impaired than patients from the A- group (N= 28) on immediate recall (A+: 5.9±2.8; A-: 7.4±2.6; p = 0.001), free recall (A+: 3.5±2.7; A-: 5.9±2.8; p ≤ 0.001), total recall (A+: 5.7±3.5; A-:7.8±2.8; p ≤ 0.001), and on number of intrusions during the recall phase (A+: 1±1.8; A-: 0.1±0.3; p = 0.002). ROC curves revealed that the best scores to discriminate A + from A- patients were immediate recall (Area under curve (AUC): 0.70), number of encoding trials (AUC: 0.73), free recall (AUC: 0.74), and total recall (AUC: 0.74).

CONCLUSION: The TNI-93's immediate, free, and total recalls are valuable tools for the 39 diagnosis of AD.

Keywords: AT(N); Alzheimer’s disease; cerebrospinal fluid biomarkers; illiteracy; memory test; neuropsychology

Publication Types